معرفی
Pierre Charneau is a leading researcher at the Institut Pasteur in Paris, where he serves as Structure Manager of a research team focused on lentiviral vector-based immunotherapies. He plays a pivotal role in the Institut Pasteur-TheraVectys Joint Laboratory, advancing preclinical and clinical development of therapeutic vaccines for cancer and infectious diseases.
His research centers on the development and application of non-integrative lentiviral vectors to stimulate robust and long-lasting T-cell immunity. Key areas include therapeutic vaccination against HPV-induced cancers, dengue, SARS-CoV-2, and mycobacterial infections. His work has demonstrated complete eradication of HPV-induced tumors in preclinical models and the induction of protective mucosal immunity via intranasal delivery.
The publication trends show a strong focus on translational immunology, with frequent contributions to high-impact journals in the fields of vaccinology, immunology, and virology. His recent articles emphasize tumor microenvironment remodeling, CD8+ and CD4+ T-cell responses, and innovative vector design for targeted antigen delivery.
- Full eradication of HPV-induced tumors using Lenti-HPV-07 (EMBO Mol Med, 2023)
- Preclinical proof of concept for a tetravalent dengue T-cell vaccine (Front Immunol, 2023)
- Intranasal lentiviral boosters enhancing mRNA vaccine immunity (Mol Ther, 2022)
- Development of dendritic cell-targeted vaccines for mycobacteria (Mucosal Immunol, 2022)
Charneau leads and collaborates on numerous preclinical projects, particularly within the Cancer Initiative at Institut Pasteur. He mentors a multidisciplinary team including PhD students, postdoctoral fellows, and research engineers. While specific grant details are not listed, his work is supported by industrial partnerships and international collaborations, particularly with TheraVectys and Shanghai Jinwei Biotechnology. His lab is instrumental in advancing lentiviral platforms toward clinical trials for HIV, hepatitis B, and multiple cancers.
He is a key member of a research unit focused on adaptive and cellular immunity, working closely with Laleh Majlessi and other senior scientists. The team operates within advanced biosafety and animal model facilities at the Institut Pasteur, enabling high-impact studies on viral pathogenesis and vaccine efficacy. Future work is expected to expand into personalized cancer vaccines and pan-coronavirus immunity.
